New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Pionyr Immunotherapeutics to Present on Myeloid Tuning Platform and TREM1 Targeting Antibody Program at the Tumor Myeloid-Directed Therapies Summit
-
Alternative Investment Platform Yieldstreet Partners with Wonder Group, the Company Redefining At-Home Dining and Food Delivery, to Offer Investors Access to the Startup’s Series B Funding Round
-
Metacrafters.io Raises $4.5M for Web3 Developers with Multichain Grants from Solana, Flow, Avalanche, and Polygon Foundations
-
Kira Learning Announces $6 Million Seed Round Financing Led by NEA and Dr. Andrew Ng’s AI Fund
-
4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing
-
4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing
-
Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases
-
Form SC 13D/A IonQ, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13D/A GENOCEA BIOSCIENCES, Filed by: New Enterprise Associates 16, L.P.
-
New Wave Foods Welcomes Taylor Crown as New Board Member
-
Pionyr Immunotherapeutics’ Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022
-
Assembled Raises $51 Million led by NEA to Accelerate Workforce Management Platform
-
Stablix Appoints Eddine Saiah Chief Scientific Officer and Expands Leadership Team
-
Form SC 13D/A IMARA Inc. Filed by: New Enterprise Associates 14, L.P.
-
VIPC’s Virginia Venture Partners Invests in Magazine Jukebox, Inc. to Provide Digital Alternative to Traditional Magazine Displays
-
VIPC’s Virginia Venture Partners Invests in Magazine Jukebox, Inc. to Provide Digital Alternative to Traditional Magazine Displays
-
AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia
-
AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
-
Timescale Announces OpenTelemetry Tracing Support for Promscale
-
Celcuity (CELC) Announces $100M Private Placement
-
Celcuity Inc. Announces $100 Million Private Placement
-
AviadoBio Announces Formation of Scientific Advisory Board
-
AviadoBio Announces Formation of Scientific Advisory Board
-
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
-
Form SC 13D/A Nkarta, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13D/A Robinhood Markets, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Lumos Pharma, Inc. (LUMO) Enters Collaboration with Massachusetts General Hospital to Evaluate LUM-201
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
-
Revelle Aesthetics Unveils New Minimally Invasive Procedure for Cellulite Reduction at Premier Aesthetic Plastic Surgery Conference
-
Form 4 Robinhood Markets, Inc. For: May 02 Filed by: New Enterprise Associates 17, L.P.
-
Sentry Raises $90 Million in Series E Funding to Expand and Drive Adoption of Developer-first Application Monitoring
-
AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022
-
Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board
-
AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia
-
AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia
-
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
-
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
-
Slone Partners Places Richard B. Bartram as Chief Financial Officer at MBX Biosciences
-
Form SC 13D/A IMARA Inc. Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
-
SOSV RELEASES CLIMATE TECH 100 LIST FOR 2022
-
Wheelhouse Spins out of Lyric With $16 Million in Funding Led by Highgate Ventures and NEA to Strengthen Leadership Position in Accommodation & Rental Software
-
VIPC’s Virginia Venture Partners Invests in Humanitru to Enhance Fundraising Efforts Conducted by Nonprofits
-
Glacier Raises $4.5M to Combat Climate Change with AI-Powered Recycling Robots
-
Multi-Camera 3D Vision Company NODAR Secures $12 Million in Funding from NEA

